Marked-up Claim:

9. (Amended) The compound or salt of Claim $\underline{\mathbf{6}}$ 1 wherein \mathbf{R}^6 is $-\mathrm{COR}^{10}$ wherein R_{10} is $-\mathrm{NR}^{11}(\mathrm{CH}_2)_n\mathrm{R}^{12}$ wherein:

R₁₁ is hydrogen or lower unsubstituted alkyl;

n is 2 or 3; and

 R^{12} is -NR¹³R¹⁴ wherein R₁₃ and R₁₄ combine to form a group selected from -(CH₂)₄-, -(CH₂)₅-, -(CH₂)₂-O-(CH₂)₂- [or]and -(CH₂)₂N(CH₃)(CH₂)₂-.

- 12. (Amended) The compound or salt of Claim **6**1 wherein R₆ is 3-pyrrolidin-1-ylpropylaminocarbonyl, 3-morpholin-4-ylpropylamino-carbonyl, 2-pyrrolidin-1-ylethylamino-carbonyl, 2-morpholin-4-ylethylaminocarbonyl, 2-(4-methylpiperazin-1-yl)ethyl-aminocarbonyl, 3-(4-methylpiperazin-1-yl)propylamino-carbonyl or 3-(3,5-dimethylpiperazin-1-yl)propylamino-carbonyl.
- 15. (Amended) The compound or salt of Claim $\underline{\mathbf{6}}$ 1 wherein R_6 is $-COR_{10}$ wherein R_{10} is $-NR_{13}R_{14}$ wherein R_{13} is hydrogen and R_{14} is lower alkyl substituted with hydroxy, aryl, heteroalicyclic, heteroaryl, or carboxy.
- 20. (Amended) The compound or salt of Claim $\underline{\bf 6}$ 1 wherein R^6 is $-COR^{10}$ wherein R^{10} is $-NR^{11}(CH_2)_nR^{12}$ wherein:

R¹¹ is hydrogen or lower unsubstituted alkyl;

n is 2 or 3; and

R¹² is -NR¹³R¹⁴ wherein R¹³ and R¹⁴ together combine to form a heterocycle.

21. (Amended) The compound or salt of Claim $\underline{\bf 6}1$ wherein R^6 is $-COR^{10}$ wherein R^{10} is $-NR^{11}(CH_2)_nR^{12}$ wherein:

 R^{11} is hydrogen or lower unsubstituted alkyl;

n is 2 or 3; and



R¹² is -NR¹³R¹⁴ wherein R¹³ and R¹⁴ together combine to form a 5, 6 or 7 atom heterocycle containing a carbonyl group and one or two nitrogen atoms within the ring.

- 22. (Amended) The compound or salt of Claim **6**1 wherein R⁶ is 2-(3-oxopiperazin-1-yl)ethylaminocarbonyl, 2-(imidazolidin-l-yl-2-one)ethylaminocarbonyl, 2-(tetrahydropyrimidin-1-yl-2-one)ethylaminocarbonyl, 2-(2-oxopyrrolidin-1-yl)ethylaminocarbonyl, 3-(3-oxopiperazin-1-yl)propylaminocarbonyl, 3-(imidazolidin-1-yl-2-one)propyl-aminocarbonyl, 3-(tetrahydropyrimidin-1-yl-2-one)-propylaminocarbonyl, or 3-(2-oxopyrrolidin-1-yl)propyl-aminocarbonyl.
 - 32. (Amended) The compound or salt of Claim [25]61 wherein:

R¹ is hydrogen;

R² is hydrogen, cyano, fluoro, chloro, or bromo;

R³ is phenyl; and

R⁴ is hydrogen.

33. (Amended) The compound or salt of Claim $\underline{\mathbf{6}}1$ wherein:

R¹ is hydrogen, unsubstituted lower alkyl, -C(O)NR⁸R⁹, unsubstituted cycloalkyl or aryl;

 R^2 is hydrogen, halo, lower alkoxy, cyano, aryl or $-S(O)_2NR^{13}R^{14}$ wherein R^{13} is hydrogen and R^{14} is hydrogen, aryl or alkyl;

 R^3 is selected from the group consisting of hydrogen, lower alkoxy, -C(O) R^{15} , -N R^{13} C(O) R^{14} , aryl, and heteroaryl; and

R⁴ is hydrogen.

- 43. (Amended) The compound of Claim $\underline{6}1$ wherein R^6 is $-COR^{10}$ wherein R^{10} is $-NR^{11}(CH_2)_nR^{12}$ wherein R^{12} is $-N^+(O^-)[N]R^{13}R^{14}$ [or $N(OH)R^{13}$] wherein R^{13} and R^{14} are independently selected from the group consisting of unsubstituted lower alkyl.
- 44. (Amended) The compound of Claim <u>6</u>1 wherein R⁶ is [2 (N hydroxy N ethylamino)ethylaminocarbonyl or] 2-[N⁺(O⁻)(C₂H₅)₂]ethyl-aminocarbonyl.



46. (Amended) The compound or salt of [any of the] Claim[s] [39, 40, 43, 44 or 20 22]61 wherein:

R⁵ is selected from the group consisting of hydrogen, or methyl; and

R⁷ is selected from the group consisting of methyl, hydrogen or phenyl.

47. (Amended) The compound or salt of Claim [45]61 wherein:

R¹ is hydrogen;

R² is hydrogen, cyano, chloro, fluoro, or bromo;

R³ is hydrogen; and

R⁴ is hydrogen.

48. (Amended) The compound or salt of Claim [46]61 wherein:

R¹ is hydrogen;

R² is cyano, chloro, fluoro, or bromo;

R³ is hydrogen; and

R⁴ is hydrogen.

- 50. (Amended) A pharmaceutical composition, comprising a compound or salt of Claim **6**1 and, a pharmaceutically acceptable carrier or excipient.
- 51. (Amended) A pharmaceutical composition, comprising a compound or salt of Claim [49]65 and, a pharmaceutically acceptable carrier or excipient.
- 52. (Amended) A method for the modulation of the catalytic activity of a protein kinase, comprising contacting said protein kinase with a compound or salt of Claim 61 or [49]65.

